Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8STS

Crystal Structure of HIV-1 Reverse Transcriptase (Y181C, V106A) varient in Complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)-4-fluorophenoxy)-7-fluoro-2-naphthonitrile (JLJ636), a non-nucleoside inhibitor

8STS の概要
エントリーDOI10.2210/pdb8sts/pdb
関連するPDBエントリー8STP 8STQ 8STR
分子名称Reverse transcriptase/ribonuclease H, p51 RT, 5-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]-4-fluorophenoxy}-7-fluoronaphthalene-2-carbonitrile, ... (5 entities in total)
機能のキーワードreverse transcriptase, antiviral, drug design, hiv-1, viral protein, hydrolase
由来する生物種Human immunodeficiency virus type 1 BH10
詳細
タンパク質・核酸の鎖数4
化学式量合計229026.96
構造登録者
Hollander, K.,Jorgensen, W.L.,Anderson, K.S. (登録日: 2023-05-11, 公開日: 2023-11-29, 最終更新日: 2023-12-13)
主引用文献Hollander, K.,Chan, A.H.,Frey, K.M.,Hunker, O.,Ippolito, J.A.,Spasov, K.A.,Yeh, Y.J.,Jorgensen, W.L.,Ho, Y.C.,Anderson, K.S.
Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise.
Protein Sci., 32:e4814-e4814, 2023
Cited by
PubMed Abstract: HIV-1 reverse transcriptase (RT) remains a key target for HIV drug development. As successful management of the disease requires lifelong treatment, the emergence of resistance mutations is inevitable, making development of new RT inhibitors, which remain effective against resistant variants crucial. To this end, previous computationally guided drug design efforts have resulted in catechol diether compounds, which inhibit wildtype RT with picomolar affinities and appear to be promising preclinical candidates. To confirm that these compounds remain potent against Y181C, a widespread mutation conferring resistance to first generation inhibitors, they were screened against the HIV-1 N119 clinical isolate, reported as a Y181C single mutant. In comparison to a molecular clone with the same mutation, N119 appears less susceptible to inhibition by our preclinical candidate compounds. A more detailed sequencing effort determined that N119 was misidentified and carries V106A in combination with Y181C. While both indolizine and naphthalene substituted catechol diethers are potent against the classical Y181C single mutant, the addition of V106A confers more resistance against the indolizine derivatives than the naphthalene derivatives. Crystal structures presented in this study highlight key features of the naphthyl group, which allow these compounds to remain potent in the double mutant, including stronger interactions with F227 and less reliance on V106 for stabilization of the ethoxy-uracil ring, which makes critical hydrogen bonds with other residues in the binding pocket.
PubMed: 37861472
DOI: 10.1002/pro.4814
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.02 Å)
構造検証レポート
Validation report summary of 8sts
検証レポート(詳細版)ダウンロードをダウンロード

237423

件を2025-06-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon